The latest research results for the treatment of novel coronavirus infection pneumonia were previously published. Abirater and darunavir effectively inhibited the virus, showing in in vitro cellular assays that abirater at concentrations of 10-30 μmol effectively inhibited coronavirus up to 60-fold compared to the drug-untreated control group, and significantly inhibited the pathogenic effect of the virus on cells. Darunavir significantly inhibited viral replication at a concentration of 300 μmol and was 280-fold more efficient compared to the drug-untreated group. However, these two drugs are prescription drugs and patients should always take them under the guidance of a physician.